Italy's Garofalo Health Care FY revenue rises as out‑of‑region services increase

About this update from Garofalo Health Care S.p.a.

OverviewItaly healthcare provider's FY2025 revenue rose 3.5% yr/yrAdjusted EBITDA for FY2025 grew 2.7%OutlookCompany expects to benefit from growing healthcare demand and aims to strengthen best-in-class positioningResult DriversOUT-OF-REGION PATIENTS - Revenue growth benefited from increased services to out-of-region patientsACQUISITIONS - Full-year contributions from Sanatorio Triestino and Gruppo Aurelia acquisitions supported revenueHIGHER ENERGY AND INSURANCE COSTS - Adjusted EBITDA was negatively impacted by higher energy costs at Terme del Friuli-Venezia GiuliaCompany press release: Key DetailsMetricBeat/MissActualConsensus EstimateFY RevenueBeatEUR 487.10 mlnEUR 480.80 mln (1 Analyst)FY Net IncomeEUR 23.60 mlnFY Adjusted EBITDAEUR 80.7 mlnAnalyst CoverageThe one available analyst rating on the shares is "strong buy"The average consensus recommendation for the healthcare facilities & services peer group is "buy."Wall Street's median 12-month price target for Garofalo Health Care SpA is €6.60, about 25.7% above its March 13 closing price of €5.25The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 17 three months agoFor questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

View stock analysis, news, and events for Garofalo Health Care S.p.a.